Research Article

Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 1

General information of patients in both groups.

CharacteristicsTreatment (n = 172)Control (n = 174) value

Gender, n (%)
Male50 (29.1)68 (39.1)
Female122 (70.9)106 (60.9)0.050
Age, mean (SD), years41.36 (9.16)42.47 (7.95)0.325

Marital status, n (%)
Unmarried27 (15.7)40 (23.0)
Married145 (84.3)134 (77.0)0.086

Education, n (%)
Bachelor degree and above27 (15.7)29 (16.7)
Senior high school47 (27.3)53 (30.4)
Junior high school40 (23.3)37 (21.3)
Primary school or below58 (33.7)55 (31.6)0.893

Monthly income, n (%)
<500 RMB3 (1.7)8 (4.6)
500–1000 RMB34 (19.8)26 (14.9)
1001–3000 RMB57 (33.2)58 (33.4)
3001–5000 RMB58 (33.7)60 (34.5)
>5000 RMB20 (11.6)22 (12.6)0.483

Smoking, n (%)67 (39.0)76 (43.7)0.372
Alcohol, n (%)56 (32.6)50 (28.7)0.441
Stroke, n (%)9 (5.2)17 (9.8)0.109
Hypertension, n (%)86 (50.0)91 (52.3)0.669
Diabetes, n (%)57 (33.1)66 (37.9)0.352
Hyperlipemia, n (%)66 (38.4)78 (44.8)0.223
Heart disease, n (%)35 (20.3)47 (27.0)0.145
Diagnosis, n (%)
Migraine with aura28 (16.3)42 (24.1)
Migraine without aura144 (83.7)132 (75.9)0.069
Duration of migraine (year)15.60 ± 8.9417.52 ± 8.740.040

Location of headache, n (%)
Left74 (43.0)72 (41.4)
Right64 (37.2)63 (36.2)
Bilateral34 (19.8)39 (22.4)0.833